CN111671966B - Medical suture line and preparation method and application thereof - Google Patents
Medical suture line and preparation method and application thereof Download PDFInfo
- Publication number
- CN111671966B CN111671966B CN202010556859.6A CN202010556859A CN111671966B CN 111671966 B CN111671966 B CN 111671966B CN 202010556859 A CN202010556859 A CN 202010556859A CN 111671966 B CN111671966 B CN 111671966B
- Authority
- CN
- China
- Prior art keywords
- framework material
- medical suture
- organic framework
- organic
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/06—At least partially resorbable materials
- A61L17/10—At least partially resorbable materials containing macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/005—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters containing a biologically active substance, e.g. a medicament or a biocide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/06—At least partially resorbable materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
Abstract
The invention relates to the field of medicines, in particular to a medical suture and a preparation method and application thereof. The method comprises the following steps: (1) dissolving Zr salt and an organic ligand according to the molar ratio of Zr ions to the organic ligand (0.5-2):1, mixing and reacting for 2-4h at 110-; (2) adding the Zr-based metal-organic framework material into an organic solvent in which the medicine is dissolved, and mixing for 2-4 days at 50-70 ℃ to obtain a medicine-loaded material; (3) the material loaded with the medicine is uniformly mixed with the sodium alginate and then fixed in a calcium chloride solution. The medical suture can omit the step of removing the suture, simplify the treatment procedure, save medical resources and reduce the burden of patients; has drug loading and slow release, and has antibacterial, wound treating and infection preventing effects.
Description
Technical Field
The invention relates to the field of medicines, in particular to a medical suture and a preparation method and application thereof.
Background
With the diversification of diseases and the continuous development of medical technology, surgery plays an important role in medical treatment, wherein suture technology is one of important factors for success of surgery. Good medical suture has important significance for the success rate of the operation.
The traditional medical suture line can not be automatically degraded in a body, has poor tissue compatibility, is usually used as a foreign body, is easy to generate a series of incision complications such as rejection, inflammatory reaction, infection, excessive scar hyperplasia and the like, and has high incidence rate of incision pain and sinus formation. In the infected incision, the tension of the silk thread is obviously reduced, and the wound can be healed only by continuously taking out the thread end when the infection of the incision is treated, so that complicated treatment steps are increased. The degradable medical suture used at present may not reach the strength when facing some wounds with larger tension, and part of the materials may cause acute inflammatory reaction.
Metal-organic framework Materials (MOFs) are porous crystalline materials emerging in recent decades and have high porosity and large Langmuir specific surface area, and the maximum specific surface area of the MOFs is about 7140m2G, the theoretical value of which is more than 10000m2(ii) in terms of/g. The Langmuir specific surface area of the traditional porous materials such as zeolite and activated carbon can only reach 1000m at most2G or 3000m2/g。
The sodium alginate aqueous solution contains a large amount of-COO-, can show polyanion behavior in the aqueous solution, has certain adhesiveness, and can be used as a drug carrier for treating mucosal tissues. The sodium alginate can quickly form gel under extremely mild conditions, and the conditions are mild, so that the inactivation of active substances such as sensitive medicines, proteins, cell nucleuses, enzymes and the like can be avoided.
Disclosure of Invention
The invention aims to solve the problems that a medical suture line in the prior art cannot be automatically degraded in vivo, has poor histocompatibility and low strength, and provides the medical suture line and a preparation method and application thereof.
In order to achieve the above objects, one aspect of the present invention provides a method for preparing a medical suture, comprising the steps of:
(1) dissolving Zr salt and an organic ligand in acetic acid according to the molar ratio of Zr ions to the organic ligand (0.5-2):1, carrying out mixed reaction at 110-130 ℃ for 2-4h, and then sequentially cooling, washing, centrifuging and drying to obtain a Zr-based metal-organic framework material;
(2) adding the Zr-based metal-organic framework material obtained in the step (1) into an organic solvent in which a medicament is dissolved, and mixing for 2-4 days at 50-70 ℃ to obtain a medicament-loaded metal-organic framework material;
(3) and (3) uniformly mixing the metal-organic framework material loaded with the medicine obtained in the step (2) with sodium alginate, then placing the mixture into a mould and fixing the mould in a calcium chloride solution.
Preferably, in step (1), the concentration of acetic acid is 40 to 50 vol%.
Preferably, in step (1), the Zr salt is ZrOCl2·8H2O or ZrCl4。
Preferably, in step (1), the organic ligand is pyridine 2, 5-dicarboxylic acid, terephthalic acid or 2-aminoterephthalic acid.
Preferably, in the step (2), the mass ratio of the Zr-based metal-organic framework material to the drug is 1 (5-15).
Preferably, in step (2), the drug is an anti-inflammatory drug and/or an analgesic drug.
Preferably, in step (2), the organic solvent is N, N-dimethylformamide, N-dimethylacetamide or N, N-diethylformamide.
Preferably, in the step (3), the mass ratio of the metal-organic framework material loaded with the medicine to the sodium alginate is 1: (5-10).
In a second aspect, the present invention provides a medical suture prepared by the above method.
In a third aspect, the present invention provides a use of the above medical suture in surgical suturing.
The antibacterial degradable medical suture with the drug slow-release effect can be prepared according to the method, the preparation method is simple, and the potential application prospect is wide; the obtained medical suture has the function of tightening wounds of common medical sutures, can achieve the aim of synchronously performing treatment and antibiosis, can be automatically degraded in a human body, and has no obvious side effect; is beneficial to improving the wound healing effect, enhancing the antibacterial and therapeutic effects and reducing the burden of patients. When in use, the traditional step of removing stitches can be omitted, the treatment procedure is simplified, the medical resources are saved, and the burden of patients is lightened; has drug loading and slow release, and has antibacterial, wound treating and infection preventing effects.
Drawings
FIG. 1 is a photograph of a medical suture line A1 of example 1;
FIG. 2 is a photograph of a medical suture D1 of comparative example 1;
fig. 3 is an XRD comparison pattern in test example 2.
Detailed Description
The following describes in detail specific embodiments of the present invention. It should be understood that the detailed description and specific examples, while indicating the present invention, are given by way of illustration and explanation only, not limitation.
The endpoints of the ranges and any values disclosed herein are not limited to the precise range or value, and such ranges or values should be understood to encompass values close to those ranges or values. For ranges of values, between the endpoints of each of the ranges and the individual points, and between the individual points may be combined with each other to give one or more new ranges of values, and these ranges of values should be considered as specifically disclosed herein.
The diversity of the organic ligands and the metal ions provides possibility for flexibly selecting the corresponding metal ions and the organic ligands according to practical application of the metal-organic framework material, and different medicaments can be loaded. Sodium alginate has good biocompatibility. The sodium alginate is combined with a metal-organic framework material capable of loading drugs by utilizing the biocompatibility and higher viscosity of the sodium alginate, so that the medical suture with the biocompatibility and the drug slow-release function can be obtained. Based on this, the present invention has been completed.
The invention provides a preparation method of a medical suture, which comprises the following steps:
(1) dissolving Zr salt and an organic ligand in acetic acid according to the molar ratio of Zr ions to the organic ligand (0.5-2):1, carrying out mixed reaction at 110-130 ℃ for 2-4h, and then sequentially cooling, washing, centrifuging and drying to obtain a Zr-based metal-organic framework material;
(2) adding the Zr-based metal-organic framework material obtained in the step (1) into an organic solvent in which a medicament is dissolved, and mixing for 2-4 days at 50-70 ℃ to obtain a medicament-loaded metal-organic framework material;
(3) and (3) uniformly mixing the metal-organic framework material loaded with the medicine obtained in the step (2) with sodium alginate, then placing the mixture into a mould and fixing the mould in a calcium chloride solution.
In a particular embodiment of the method of the present invention, in step (1), the molar ratio of Zr ions to organic ligands may be 0.5:1, 1:1, 1.5:1 or 2: 1.
In the method of the present invention, in a specific embodiment, in the step (1), the temperature of the mixing reaction may be 110 ℃, 115 ℃, 120 ℃, 125 ℃ or 130 ℃.
In the method of the present invention, in a specific embodiment, in the step (1), the mixing reaction time may be 2h, 2.5h, 3h, 3.5h or 4 h.
In the method of the present invention, in step (1), there is no particular requirement for the washing means and reagents, and there may be various means and reagents conventionally used in the art. In still another embodiment, the washing may be performed using distilled water and ethanol.
In the method of the present invention, in step (1), there is no particular requirement for the selection of the centrifugal apparatus, and it may be a routine choice in the art.
In the method of the present invention, in the step (1), there is no particular requirement for the selection of the equipment for carrying out the drying, and various drying equipment conventionally used in the art may be used. In a specific embodiment, the drying is performed in a vacuum drying oven.
In the method of the present invention, the concentration of the acetic acid in the step (1) may be 40 to 50% by volume. Specifically, for example, the volume may be 40%, 42%, 44%, 46%, 48% or 50%.
In the process of the present invention, in the step (1)The Zr salt may be ZrOCl2·8H2O or ZrCl4。
In the process of the present invention, in step (1), the organic ligand may be pyridine 2, 5-dicarboxylic acid, terephthalic acid or 2-aminoterephthalic acid.
In the method of the present invention, in the step (2), the mass ratio of the Zr-based metal-organic framework material to the drug may be 1 (5-15). Specifically, for example, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, 1:12, 1:13, 1:14, or 1:15 can be used.
In the method of the present invention, in step (2), there is no particular requirement for the selection of the drug, and various drugs conventionally used after surgery may be used. Preferably, the drug is an anti-inflammatory and/or analgesic. In specific embodiments, the drug may be ibuprofen, sodium ampicillin, procainamide hydrochloride, or the like.
In the method of the present invention, in the step (2), the organic solvent may be N, N-dimethylformamide, N-dimethylacetamide, or N, N-diethylformamide.
In the method, the Zr-based metal-organic framework material has the advantages of simple synthesis steps, readily available raw materials, safe operation and mild conditions, and different types of medicines can be selected for loading according to the wound to be sutured when the medicines are loaded, so that the function of the medical suture line is improved.
In the method of the present invention, in the step (3), the mass ratio of the drug-loaded metal-organic framework material to the sodium alginate may be 1: (5-10). Specifically, it may be 1:5, 1:6, 1:7, 1:8, 1:9 or 1:10, for example.
In the method of the present invention, in step (3), there is no particular requirement for the selection of the mold, and it may be selected according to the desired shape and size.
In a second aspect, the present invention provides a medical suture prepared by the above method.
In the invention, the medical suture is compounded by adopting a Zr-based metal-organic framework material and sodium alginate, the Zr-based metal-organic framework material is loaded with medicaments required by treatment and inflammation diminishing, and sodium alginate fiber is used as a suture main body.
In a third aspect, the present invention provides a use of the above medical suture in surgical suturing.
In the invention, the medical suture line can be used for suturing in surgical operations and medical operations, and the self-degradation characteristic of the medical suture line avoids secondary damage to human bodies caused by problems such as stitch removal and the like.
In the invention, the metal-organic framework material loaded with the medicine and the fiber attached with the medicine have good biocompatibility, can be naturally degraded in a human body and cannot cause harm to the human body. The porous metal-organic frame material may be loaded with medicine in certain amount and mixed with fiber to form suture, and the suture may be used to release medicine continuously for treating wound to diminish inflammation and to realize the simultaneous effects of resisting bacteria, treating and healing wound. The natural degradation of the suture material omits the traditional step of removing stitches, reduces a series of injuries to human bodies caused by removing stitches and simplifies the fussy postoperative rehabilitation steps.
The present invention will be described in detail by way of examples, but the scope of the present invention is not limited thereto.
Example 1
(1) ZrOCl2·8H2Dissolving O and pyridine 2, 5-dicarboxylic acid in acetic acid with the concentration of 45 volume percent according to the molar ratio of Zr ions to pyridine 2, 5-dicarboxylic acid of 1:1, mixing and reacting for 3 hours at 120 ℃, and then sequentially cooling, washing, centrifuging and drying to obtain a Zr-based metal-organic framework material;
(2) adding the Zr-based metal-organic framework material obtained in the step (1) into N, N-dimethylformamide dissolved with ibuprofen, wherein the mass ratio of the Zr-based metal-organic framework material to the ibuprofen is 1:10, and mixing for 3 days at 60 ℃ to obtain the ibuprofen-loaded metal-organic framework material;
(3) uniformly mixing the metal-organic framework material loaded with the ibuprofen and sodium alginate, wherein the mass ratio of the metal-organic framework material loaded with the ibuprofen to the sodium alginate is 1: and 7, then placing the medical suture in a mold and fixing the mold in a calcium chloride solution to obtain the medical suture A1.
Example 2
(1) ZrOCl2·8H2Dissolving O and terephthalic acid in 50 volume percent acetic acid according to the molar ratio of Zr ions to terephthalic acid of 2:1, mixing and reacting for 2 hours at 130 ℃, and then sequentially cooling, washing, centrifuging and drying to obtain a Zr-based metal-organic framework material;
(2) adding the Zr-based metal-organic framework material obtained in the step (1) into N, N-dimethylformamide dissolved with sodium ibuprofen, wherein the mass ratio of the Zr-based metal-organic framework material to the sodium ibuprofen is 1:15, and mixing for 2 days at 70 ℃ to obtain a metal-organic framework material loaded with sodium ibuprofen;
(3) uniformly mixing the metal-organic framework material loaded with the sodium ibuprofen obtained in the step (2) with sodium alginate, wherein the mass ratio of the metal-organic framework material loaded with the sodium ibuprofen to the sodium alginate is 1: and 8, then placing the medical suture in a mould and fixing the mould in a calcium chloride solution to obtain the medical suture A2.
Example 3
(1) ZrOCl2·8H2Dissolving O and 2-amino terephthalic acid in acetic acid with the concentration of 40 volume percent according to the molar ratio of Zr ions to 2-amino terephthalic acid of 0.5:1, carrying out mixed reaction for 4 hours at 110 ℃, and then sequentially carrying out cooling, washing, centrifuging and drying to obtain a Zr-based metal-organic framework material;
(2) adding the Zr-based metal-organic framework material obtained in the step (1) into N, N-dimethylformamide dissolved with procainamide hydrochloride, wherein the mass ratio of the Zr-based metal-organic framework material to the procainamide hydrochloride is 1:5, and mixing for 4 days at 50 ℃ to obtain a procainamide hydrochloride-loaded metal-organic framework material;
(3) uniformly mixing the metal-organic framework material loaded with the procainamide hydrochloride obtained in the step (2) with sodium alginate, wherein the mass ratio of the metal-organic framework material loaded with the procainamide hydrochloride to the sodium alginate is 1:9, and then placed in a mold and fixed in a calcium chloride solution to obtain the medical suture A3.
Comparative example 1
The medical suture D1 was prepared using sodium alginate alone.
Test example 1
A1 of the medical suture prepared in example 1 is shown in FIG. 1, and D1 of the medical suture prepared in comparative example 1 is shown in FIG. 2. It is apparent from the figure that there are clear white dots on the suture of fig. 1 compared to fig. 2, indicating that the Zr-based metal-organic framework material has been successfully complexed with sodium alginate.
Test example 2
The Zr-based metal-organic framework material prepared in example 1 and the ibuprofen-loaded Zr-based metal-organic framework material on the suture were examined using an X' Pert PRO diffractometer instrument of Panalytical analyzer, the netherlands, and compared with a theoretical XRD spectrum of the Zr-based metal-organic framework material, and the results are shown in fig. 3.
In fig. 3, 1 is a spectrum of the Zr-based metal-organic framework material loaded with ibuprofen on the suture, 2 is a spectrum of the Zr-based metal-organic framework material obtained in example 1, and 3 is a theoretical diagram of the Zr-based metal-organic framework material. As can be observed from the graph of fig. 3, the graph of the obtained Zr-based metal-organic framework material is the same as the theoretical graph, indicating that the expected Zr-based metal-organic framework material was successfully prepared; and as can be seen from the atlas of the Zr-based metal-organic framework material loaded with the drug ibuprofen, the structure of the Zr-based metal-organic framework material is not affected by the loading of the drug ibuprofen.
Test example 3
The drug loading content of the Zr-based metal-organic framework material in examples 1-3 was analyzed by combining the characteristic peak of nmr hydrogen spectrum, molecular formula and drug structural formula, and the drug content was calculated using formula 1, with the results shown in table 1:
TABLE 1
| Example numbering | Medicine | Drug content |
| Example 1 | Ibuprofen | 44.95％ |
| Example 2 | Ibuprofen sodium | 51.61％ |
| Example 3 | Procainamide hydrochloride | 47.87％ |
As can be seen from the results in table 1, the medical suture prepared by the method of the present invention shows excellent drug loading performance, and the MOFs can also have good drug release performance according to the structural characteristics of the metal-organic framework material itself.
The preferred embodiments of the present invention have been described above in detail, but the present invention is not limited thereto. Within the scope of the technical idea of the invention, many simple modifications can be made to the technical solution of the invention, including combinations of various technical features in any other suitable way, and these simple modifications and combinations should also be regarded as the disclosure of the invention, and all fall within the scope of the invention.
Claims (8)
1. A method for preparing a medical suture, which is characterized by comprising the following steps:
(1) dissolving Zr salt and an organic ligand in acetic acid according to the molar ratio of Zr ions to the organic ligand (0.5-2):1, carrying out mixed reaction at 110-130 ℃ for 2-4h, and then sequentially cooling, washing, centrifuging and drying to obtain a Zr-based metal-organic framework material;
(2) adding the Zr-based metal-organic framework material obtained in the step (1) into an organic solvent in which a medicament is dissolved, and mixing for 2-4 days at 50-70 ℃ to obtain a medicament-loaded metal-organic framework material;
(3) uniformly mixing the metal-organic framework material loaded with the medicine obtained in the step (2) with sodium alginate, then placing the mixture into a mould and fixing the mould in a calcium chloride solution;
in step (1), the organic ligand is pyridine 2, 5-dicarboxylic acid, terephthalic acid or 2-aminoterephthalic acid.
2. The method for producing a medical suture according to claim 1, wherein the concentration of acetic acid in the step (1) is 40 to 50 vol%.
3. The method for producing a medical suture according to claim 1 or 2, wherein in the step (1), the Zr salt is ZrOCl2·8H2O or ZrCl4。
4. The method for preparing a medical suture according to claim 1, wherein in the step (2), the mass ratio of the Zr-based metal-organic framework material to the drug is 1 (5-15).
5. The method of manufacturing a medical suture according to claim 4, wherein, in the step (2), the drug is an anti-inflammatory drug and/or an analgesic drug.
6. The method for producing a medical suture according to claim 1, wherein in the step (2), the organic solvent is N, N-dimethylformamide, N-dimethylacetamide, or N, N-diethylformamide.
7. The method for preparing a medical suture according to claim 1, wherein in the step (3), the mass ratio of the drug-loaded metal-organic framework material to the sodium alginate is 1: (5-10).
8. A medical suture produced by the method of any one of claims 1 to 7.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010556859.6A CN111671966B (en) | 2020-06-17 | 2020-06-17 | Medical suture line and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010556859.6A CN111671966B (en) | 2020-06-17 | 2020-06-17 | Medical suture line and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111671966A CN111671966A (en) | 2020-09-18 |
| CN111671966B true CN111671966B (en) | 2022-01-28 |
Family
ID=72455536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010556859.6A Active CN111671966B (en) | 2020-06-17 | 2020-06-17 | Medical suture line and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111671966B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115192762B (en) * | 2022-08-15 | 2023-11-28 | 浙江理工大学 | Medical composite material and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0772465A1 (en) * | 1994-07-15 | 1997-05-14 | E.R. SQUIBB & SONS, INC. | Alginate fibres, manufacture and use |
| CN104631118A (en) * | 2015-01-22 | 2015-05-20 | 浙江理工大学 | Absorbable antibacterial alginate fibers |
| CN108441982A (en) * | 2018-02-13 | 2018-08-24 | 浙江工业大学 | A kind of preparation method of graphene/metal organic frame composite fibre |
| CN108854967A (en) * | 2018-06-08 | 2018-11-23 | 中国科学院合肥物质科学研究院 | A kind of zirconium-based metallic organic framework materials UiO-66 and its application |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB579004A (en) * | 1943-11-12 | 1946-07-19 | Ernest Gordon Greville | Improved surgical sutures and like surgical material and the manufacture thereof |
| CN101721739B (en) * | 2008-10-10 | 2013-02-13 | 陈东 | Polymer composite fiber surgical suture line capable of sustaining and controlling release of therapeutic medicaments and preparation method thereof |
| US9278113B2 (en) * | 2009-03-30 | 2016-03-08 | The Board Of Regents, The University Of Texas System | Titanium dioxide nanotubes for production and delivery of nitric oxide and methods for production thereof |
| ITTO20120258A1 (en) * | 2012-03-21 | 2013-09-22 | Fond Istituto Italiano Di Tecnologia | POLYMERIC COMPOSITE MATERIALS WITH ANTIMICROBIAL AND BIODEGRADABLE PROPERTIES AND THEIR USES. |
| CN103436992B (en) * | 2013-08-29 | 2015-05-20 | 浙江理工大学 | Method for preparing nano drug-carrying capsule-loaded alginate fibers |
| CN106267300B (en) * | 2015-05-14 | 2020-09-15 | 北京化工大学 | Multifunctional material with sterilization and hemostasis performance and biochemical warfare agent protection performance and preparation method thereof |
| KR102050597B1 (en) * | 2018-01-02 | 2019-12-03 | 재단법인대구경북과학기술원 | METOHD OF in situ preparATION OF a metal-organic framework from a diffusion-control within an ionic polymer |
| CN110124034B (en) * | 2019-05-29 | 2021-02-19 | 浙江大学 | Nano metal organic framework cavitation material, synthetic method and application |
| CN110591110A (en) * | 2019-10-08 | 2019-12-20 | 浙江理工大学 | Mn-based metal-organic framework material, preparation method and application |
| CN111187421B (en) * | 2020-01-15 | 2022-02-22 | 浙江理工大学 | Nanoparticle/metal-organic framework material and preparation method and application thereof |
-
2020
- 2020-06-17 CN CN202010556859.6A patent/CN111671966B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0772465A1 (en) * | 1994-07-15 | 1997-05-14 | E.R. SQUIBB & SONS, INC. | Alginate fibres, manufacture and use |
| CN104631118A (en) * | 2015-01-22 | 2015-05-20 | 浙江理工大学 | Absorbable antibacterial alginate fibers |
| CN108441982A (en) * | 2018-02-13 | 2018-08-24 | 浙江工业大学 | A kind of preparation method of graphene/metal organic frame composite fibre |
| CN108854967A (en) * | 2018-06-08 | 2018-11-23 | 中国科学院合肥物质科学研究院 | A kind of zirconium-based metallic organic framework materials UiO-66 and its application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111671966A (en) | 2020-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105778126B (en) | Genipin cross-linked biogel and preparation method and application thereof | |
| US3988411A (en) | Spinning and shaping poly-(N-acetyl-D-glucosamine) | |
| CN108714234B (en) | Biodegradable graphene oxide composite fiber membrane and preparation method and application thereof | |
| US20080286321A1 (en) | Polymer No Donor Predrug Nanofiber Coating for Medical Devices and Therapy | |
| US9034355B2 (en) | Materials for modulating biological responses and methods of making | |
| CN107261195B (en) | Preparation method and application of antibacterial biomass gel net for sports wound rehabilitation dressing | |
| CN111671966B (en) | Medical suture line and preparation method and application thereof | |
| CN112516372A (en) | Composite drug-loaded fiber for absorbable surgical suture | |
| CN113425890A (en) | Bionic hydrogel tissue adhesive and preparation method thereof | |
| CN110354298B (en) | Preparation method of in-situ crosslinked silver nanowire/polycaprolactone surgical suture | |
| CN110665045B (en) | Gynaecology and obstetrics is with absorbing stylolite | |
| CN113817326A (en) | Multifunctional catechol hydrogel dressing and preparation method and application thereof | |
| CN114808229A (en) | High-strength medical suture for children and preparation method thereof | |
| CN112870451B (en) | Nerve sheath tube and preparation method and application thereof | |
| CN113171488B (en) | Absorbable suture line and preparation method thereof | |
| KR20190012958A (en) | Medicinal suture yarn coated with polydeoxyribonucleotide and method of manufacturing the same | |
| CN108853563B (en) | Preparation method of absorbable suture line | |
| CN112999411B (en) | Silk protein nanofiber gel dressing with pressure spreadability, and preparation method and application thereof | |
| CN108939136B (en) | Dressing for nasal filling hemostasis and preparation method thereof | |
| CN113616847A (en) | Calamine hemostatic compound based on Y molecular sieve carrier and preparation thereof | |
| CN112741926A (en) | Polyethylene-vinyl alcohol/gelatin composite electrostatic spinning wound dressing and preparation method thereof | |
| CN105664229A (en) | Medical collagen silk thread and preparation method thereof | |
| CN115105621B (en) | Preparation method of silk-spider silk composite silk fibroin nano-microspheres containing chitosan modified graphene oxide | |
| CN113855851B (en) | Hydrogel and preparation method and application thereof | |
| CN115895280B (en) | Photosensitive silk fibroin hydrogel and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |